Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Bjrnstad syndrome is characterized by congenital sensorineural hearing loss and pili torti. Less than fifty cases have been reported so far. The hearing loss usually becomes evident very early in life, often in the first year. Pili torti, a condition in which the hair shaft is flattened and twisted, makes the hair very brittle and patients develop hair loss in the first two years of life. Bjrnstad syndrome is transmitted as an autosomal recessive condition. It is caused by mutations in the BCS1L gene. Mutations in this gene also cause GRACILE syndrome.
Features include always present findings: Anhidrosis; and very common findings: Alopecia, Brittle hair, Inner ear hearing loss (sensorineural hearing impairment), and Pili torti and others. 16 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 2 | Anhidrosis, Alopecia |
BCS1L encodes BCS1 ubiquinol-cytochrome c reductase complex chaperone (419 aa). Chaperone necessary for the incorporation of Rieske iron-sulfur protein UQCRFS1 into the mitochondrial respiratory chain complex III. Highest expression in Cervix Endocervix (49.0 TPM) and Cervix Ectocervix (46.8 TPM).
Bjornstad syndrome is caused by mutations in the BCS1L gene on chromosome 2.
The BCS1L protein participates in BCS1L:LETM hexamer and LETM1 exchanges protons (mitochondrial intermembrane space) for calcium (mitochondrial matrix) pathways.
BCS1L is classified as a druggable target (Transporter category) with score 0.0.
Genetic testing for BCS1L is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 6 very common features, 4 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Bjornstad syndrome.
5 publications have been identified in PubMed for Bjornstad syndrome. Research spans Case Report / Case Series (80%) and Review / Meta-Analysis (20%).
Li X (2026). [PMID: 41814923](https://pubmed.ncbi.nlm.nih.gov/41814923/). *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG*. [Case Report / Case Series]
Orbach R (2025). [PMID: 40660675](https://pubmed.ncbi.nlm.nih.gov/40660675/). *Annals of clinical and translational neurology*. [Case Report / Case Series]
Capaci V (2025). [PMID: 40332224](https://pubmed.ncbi.nlm.nih.gov/40332224/). *International journal of molecular sciences*. [Case Report / Case Series]
Zhang X (2025). [PMID: 41466500](https://pubmed.ncbi.nlm.nih.gov/41466500/). *International journal of dermatology*. [Case Report / Case Series]
Čunátová K (2024). [PMID: 39053894](https://pubmed.ncbi.nlm.nih.gov/39053894/). *Journal of inherited metabolic disease*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 17, 2026, 10:23 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Bjornstad syndrome
1 |
Inner ear hearing loss (sensorineural hearing impairment) |
Hormones | 1 | Hypogonadism |
Brain and nerves | 1 | Intellectual disability |
Eyes | 1 | Abnormality of the eye |
AI-curated news mentioning Bjornstad syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.